Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016

  • ID: 3743731
  • Report
  • 75 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Aeterna Zentaris Inc.
  • Alize Pharma SAS
  • AstraZeneca Plc
  • Asubio Pharma Co., Ltd.
  • Asubio Pharma Co., Ltd.
  • Helsinn Healthcare S.A.
  • MORE
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016

Summary

‘Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016’, provides in depth analysis on Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR)
- The report reviews Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aeterna Zentaris Inc.
  • Alize Pharma SAS
  • AstraZeneca Plc
  • Asubio Pharma Co., Ltd.
  • Asubio Pharma Co., Ltd.
  • Helsinn Healthcare S.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) Overview

Therapeutics Development

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Stage of Development

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Therapy Area

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Indication

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Companies

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Universities/Institutes

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Aeterna Zentaris Inc.

Asubio Pharma Co., Ltd.

Asubio Pharma Co., Ltd.

Alize Pharma SAS

Helsinn Healthcare S.A.

Pfizer Inc.

RaQualia Pharma Inc.

Rhythm Pharmaceuticals, Inc.

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Drug Profiles

anamorelin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-12861903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-51 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Ghrelin Receptor for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Ghrelin Receptor for Alcoholism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inverse Agonize Ghrelin Receptor for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Dormant Projects

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Discontinued Products

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Featured News & Press Releases

Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Apr 04, 2016: Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia

Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology

Jan 19, 2016: Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen

Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL

Nov 19, 2015: Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen for the evaluation of AGHD

Oct 29, 2015: Alize Pharma reports positive safety and efficacy results from a Phase Ib trial of AZP-531 in type 2 diabetes and provides an update on its overall clinical program

Sep 09, 2015: Additional data for anamorelin in ROMANA 1 and ROMANA 2 studies

Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD

May 26, 2015: Aeterna Zentaris’ Confirmatory Phase 3 Study for Macrilen in AGHD Meets EMA’s Study-Design Expectations

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Aeterna Zentaris Inc., H1 2016

Pipeline by Asubio Pharma Co., Ltd., H1 2016

Pipeline by Alize Pharma SAS, H1 2016

Pipeline by Helsinn Healthcare S.A., H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by RaQualia Pharma Inc., H1 2016

Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016

Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aeterna Zentaris Inc.
  • Alize Pharma SAS
  • AstraZeneca Plc
  • Asubio Pharma Co., Ltd.
  • Asubio Pharma Co., Ltd.
  • Helsinn Healthcare S.A.
  • MORE
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Growth Hormone Secretagogue Receptor Type 1 – Pipeline Review, H1 2016, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity. The molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AstraZeneca Plc
Aeterna Zentaris Inc.
Asubio Pharma Co., Ltd.
Asubio Pharma Co., Ltd.
Alize Pharma SAS
Helsinn Healthcare S.A.
Pfizer Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll